Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL)

BACKGROUND: Ibrutinib is an active therapy with acceptable safety profile for patients with CLL, including high-risk patients with del17p or with TP53 mutations. Ibrutinib is broadly indicated for the treatment of patients with chronic lymphocytic leukemia and specifically including those with 17p d...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Jain, Preetesh, Keating, Michael, Wierda, William, Sivina, Mariela, Thompson, Philip A., Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, O'Brien, Susan, Burger, Jan A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5397369/
https://ncbi.nlm.nih.gov/pubmed/27797975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1948
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak